Unanswered questions in frontline bladder cancer
Phillip Palmbos, MD, PhD, assistant professor, University of Michigan Health, Assistant Professor, University of Michigan Health, describes 4 key unmet questions in the first-line and neoadjuvant bladder cancer settings.
The first question is whether or not there is a role for combination chemoimmunotherapy in first-line bladder cancer in light of the phase 3 IMvigor130 (NCT02807636) and KEYNOTE-361 (NCT02853305) trials not demonstrating a statistically significant improvement in overall survival with frontline chemoimmunotherapy combinations. The second question is whether or not there is a role for newer antibody-drug conjugates, such as enfortumab vedotin and sacituzumab govitecan, with or without chemotherapy in earlier stages of disease. The third question is, “What’s the role of immunotherapy and other new agents in the neoadjuvant space?” and the fourth question is, “What is the optimal adjuvant therapy for high-risk muscle-invasive bladder cancer patients who did not receive prior chemotherapy in the neoadjuvant space?”
FDA grants cretostimogene grenadenorepvec Breakthrough and Fast Track Designations for NMIBC
December 5th 2023The designations, which will expedite the development and regulatory review of cretostimogene grenadenorepvec in this setting, are supported by results from the phase 3 BOND-003 trial.
Speaking of Urology Podcast: Dr. Ritch and Dr. Katz discuss new bladder cancer management app
December 7th 2021“It's not a replacement for clinical judgment, obviously. But at the end of the day, the idea is that it shows you what your next steps are based on what the American Urological Association and [Society of Urologic Oncology] guidelines are for non-muscle invasive bladder cancer,” Chad R. Ritch, MD, MBA, FACS.
Updates on advanced bladder cancer treatment
October 30th 2023"If a patient begins treatment with platinum-based chemotherapy and maintenance immune checkpoint inhibition, second-line options may involve evaluating erdafitinib, ADCs, or participation in clinical trials," says Adanma Ayanambakkam, MD.
